Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeDropped

Termination of the Infertility Treatment Agreement With JCR Pharmaceuticals Co., Ltd.

First written in FY2022-Q3. 1 of 1 entries say "Dropped", first in FY2022-Q3. Latest entry: FY2022-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Termination of Infertility Treatment Agreement with JCR PharmaA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3DroppedAnnual report

    「Technology license agreement Contracting company: Asuka Pharmaceutical Co., Ltd. Counterparty: JCR Pharmaceuticals Co., Ltd. Country: Japan Product: Infertility treatment Terms: Licensed development, manufacturing and commercialization rights Term: From March 2007 until termination or cancellation in accordance with the agreement」

    JCRファーマ株式会社から許諾を受けていた不妊症治療剤の開発・製造・販売権契約を、終了した重要な契約として記載している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.